In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Professor Jane Armitage
Speaker
Professor Jane Armitage
Jane Armitage Jane Armitage

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

Specialities : Risk Factors and Prevention , Pharmacology and Pharmacotherapy, Public Health and Health Economics

Jane Armitage is Professor of Clinical Trials and Epidemiology in the Nuffield Department of Population Health (NDPH) at the University of Oxford and Honorary Consultant in Public Health Medicine at the Oxford University Hospital. She joined the Clinical Trial Service Unit, now part of NDPH, in 1990 from a background in clinical medicine, with particular experience in respiratory medicine, geriatrics and diabetes. She has co-ordinated a series of large-scale randomised trials including the MRC/BHF Heart Protection Study, SEARCH and HPS2-THRIVE, which are trials of lipid modification in people with or at risk of vascular disease, as well as the ASCEND trial of aspirin and fish oils in diabetes. Her main research interests are in lipids and the epidemiology of cardiovascular and other chronic disease. She is Course Director for the Oxford University Master’s in Clinical Trials starting in 2020.

11 presentations from this speaker

Triglyceride-rich lipoproteins: is weight loss the solution?

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2021

  • Session : Dyslipidaemia and type 2 diabetes - the two ugly sisters
  • Speaker : J Armitage (Oxford,GB)

Case - Post-myocardial infarction: when to start lipid lowering therapy and how low to go?

Event : ESC Congress 2020

  • Session : Guidelines in Practice - Messages from the 2019 ESC Dyslipidemias Guidelines
  • Speaker : J Armitage (Oxford,GB)

Should we lower triglycerides?

Event : ESC Congress 2020

  • Session : From Lifetime Risk to Real Life: Decreasing Cardiovascular Risk with Lipid Lowering
  • Speaker : J Armitage (Oxford,GB)
  • Joint with the European Atherosclerosis Society (EAS)

Aspirin is out for primary prevention of cardiovascular disease - PRO.

Event : ESC Congress 2019

  • Session : Controversies in antithrombotic treatment for primary and secondary prevention
  • Speaker : J Armitage (Oxford,GB)

Fish oil: it's all about triglycerides - CON

Event : ESC Congress 2019

  • Session : Controversies in secondary prevention: treating residual risk
  • Speaker : J Armitage (Oxford,GB)

New Master programme on Clinical Trials with University of Oxford

Event : ESC Congress 2019

  • Session : Launch of new Oxford Master’s in Clinical Trials
  • Speaker : J Armitage (Oxford,GB)

ASCEND - ASS / ASCEND- Omega 3.

Event : ESC Congress 2018

  • Session : Meet the trialist - ASCEND - Randomized trial of aspirin versus placebo for primary cardiovascular prevention in 15,480 people with diabetes & Randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 people with diabetes
  • Speaker : J Armitage (Oxford,GB), L Bowman (Oxford,GB)

PCSK9 Inhibitors - State of the art

Event : ESC Congress 2018

  • Session : PCSK9 inhibitors - For the many or the few?
  • Speaker : J Armitage (Oxford,GB)

Inhibition of cholesterol absorption - how to interpret the results of IMPROVE-IT?

Event : ESC Congress 2014

  • Session : Critical review of innovations in lipid-lowering therapy
  • Speaker : J Armitage (Oxford,GB)

High-density lipoprotein lowering trials: what went wrong?

Event : ESC Congress 2013

  • Session : The high-density lipoprotein story: waiting for a happy ending
  • Speaker : J Armitage (Oxford,GB)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are